Market
How many additional indications will Lirafugratinib be approved for by end of 2026?
2
Resolution / Starting Odds
None • 25%
One • 25%
Two • 25%
Three or more • 25%
Official announcements from relevant health authorities and Relay Therapeutics
Story
Relay and Elevar Sign Licensing Deal for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma, Potentially Worth $500 Million
Dec 3, 2024, 01:04 PM
Relay Therapeutics and Elevar Therapeutics have entered into an exclusive global licensing agreement for Lirafugratinib, a treatment aimed at FGFR2-driven cholangiocarcinoma and other solid tumors. Under the terms of the agreement, Relay Therapeutics is set to receive up to $500 million in total, which includes $75 million in upfront and regulatory milestone payments, as well as up to $425 million in potential commercial milestone payments and tiered royalties in the low-teens percentage range. This collaboration is expected to enhance Relay's oncology pipeline, particularly in addressing challenging cancer types.
View original story
Similar markets
None • 25%
One • 25%
Three or more • 25%
Two • 25%
Two • 25%
One • 25%
None • 25%
Three or more • 25%
2 • 25%
1 • 25%
0 • 25%
3 or more • 25%
Yes • 50%
No • 50%
3 or more • 25%
None • 25%
1 • 25%
2 • 25%
Approved in both US and EU • 25%
Not approved in US or EU • 25%
Approved in EU • 25%
Approved in US • 25%
No • 50%
Yes • 50%
30 to 60 countries • 25%
Fewer than 30 countries • 25%
More than 90 countries • 25%
60 to 90 countries • 25%
More than 3 trials • 25%
1 trial • 25%
2 trials • 25%
3 trials • 25%